EGFR and non-small cell lung carcinoma: Although three generations of EGFR-TKI have been approved for treating NSCLC patients carrying ECFR mutations in clinical practice, acquired drug resistance inevitably occurs in patients receiving EGFR-TKI, such as Osi (Wu and Shih, 2018).